By Lucy Rana and Huda Jafri
Introduction
In patent law, time is not just a measure, it is a strategy. Every filing, disclosure, and procedural decision carries commercial consequences that often outweigh the invention itself. Among all mechanisms in the Indian patent system, opposition stands out as the point where law, timing, and competitive strategy intersect most sharply.
Unlike many jurisdictions where validity challenges are primarily court-driven, India provides a uniquely layered pre-litigation framework that enables third parties to intervene early, and meaningfully, in the life of a patent. These interventions are not merely defensive tools; they function as strategic instruments capable of influencing claim scope, delaying exclusivity, or strengthening patent portfolios.
It is within this architecture that the opposition regime under Sections 25(1) and 25(2) of the Patents Act, 1970 operates, not as procedural background noise, but as a defining stage in the lifecycle of a patent.
Understanding its structure and consequences is therefore essential for both patentees and competitors.
A patent is, in commercial terms, an asset on a calendar. It vests on grant, runs for twenty years from the date of filing, and is traded throughout its lifecycle. Most strategic decisions around it, by patentees, competitors, investors, and licensees, are made not after grant, but during the window before and immediately after it.
In India, that window is the opposition window, broader and more consequential than in many comparable jurisdictions.
For patentees, this period reflects uncertainty: the asset is vulnerable, licensing value is not fully settled, and enforceability may be contested. For competitors, it represents a structured opportunity to challenge exclusivity before it fully crystallises.
The most consequential moment in a patent’s life is often not grant, but the decision whether or not to oppose.
The Architecture
India provides two key administrative mechanisms to challenge a patent before resorting to court litigation.
This framework is governed by Section 25 of the Patents Act, 1970, read with Rule 55 (pre-grant opposition) and Rules 55A to 63 (post-grant opposition) of the Patents Rules, 2003.
Pre-grant opposition (Section 25(1))
Pre-grant opposition is available to “any person.” Standing is broad. It may be filed after publication of the application and before grant, on any of the eleven statutory grounds.
The process is governed by Rule 55 and involves representation by the opponent, response by the applicant, and hearing where considered necessary, followed by a reasoned decision of the Controller.
The procedure operates as part of the examination process rather than a fully adversarial adjudication.
Note: Following recent amendments to the Patent Rules, applicants and practitioners must refer to the prevailing fee schedule and Form 7A requirements, rather than assuming the process is fee-free.
Post-grant opposition (Section 25(2))
Post-grant opposition is available only to a “person interested” and must be filed within one year from the date of publication of grant of the patent.
The process is more structured. An Opposition Board consisting of three Examiners is constituted under Section 25(3) to examine the matter and submit a recommendation to the Controller, who then issues a reasoned order after hearing both parties.
Both mechanisms rely on substantially corresponding statutory grounds but differ in procedural intensity and legal consequences.
Pre-grant opposition prevents finalisation of rights. Post-grant opposition challenges an already vested statutory monopoly.
The Eleven Grounds
The eleven grounds under Sections 25(1) and 25(2) fall broadly into three categories.
-
Prior art grounds
Clauses (b), (c), and (d) relate to prior publication, prior claiming, and prior public knowledge or use. These are assessed through established doctrines of novelty and anticipation.
- Biswanath Prasad Radhey Shyam v. Hindustan Metal Industries Ltd. remains a leading authority on novelty, inventive step, and the distinction between invention and mere workshop improvement.[1]
- Monsanto Co. v. Coromandel Indag Products (P) Ltd. is frequently cited on public knowledge, prior use, and lack of novelty.[2]
-
Patentability grounds
Clause (e) relates to lack of inventive step. Clause (f) addresses non-patentable subject matter under Section 3.
Section 3(d) plays a central role in pharmaceutical cases by requiring enhanced therapeutic efficacy for derivative inventions. The Supreme Court’s decision in Novartis AG v. Union of India remains the leading authority on this interpretation.[3]
Section 3(k) excludes computer programs “per se” from patentability and continues to define the boundaries of software-related inventions.
-
Procedural and disclosure grounds
Clause (g) relates to insufficiency of disclosure. Clauses (j) and (k) relate to traditional knowledge. Clause (i) relates to convention priority compliance.
Clause (h), relating to Section 8 foreign filing disclosure requirements, remains a significant procedural ground. Indian courts have consistently treated non-compliance seriously; however, its impact is contextual rather than automatic, and revocation is not triggered mechanically. Courts examine materiality, conduct, and surrounding facts.
The Opponent’s Strategic Calculus
-
Pre-grant or post-grant?
Pre-grant opposition is cost-effective and accessible, but it forms part of the examination process rather than a full adversarial adjudication.
In UCB Farchim SA v. Cipla Ltd., the Delhi High Court clarified that pre-grant opposition is best understood as being “in aid of examination,” rather than a fully inter partes proceeding.[4]
Post-grant opposition is more formal, structured, and evidentiary in nature.
-
When does limitation begin?
In Dr. Snehlata C. Gupte v. Union of India, the Delhi High Court clarified the distinction between administrative acts and the legal effect of grant. Importantly, Section 25(2) itself provides that post-grant opposition must be filed within one year from the date of publication of grant[5].
-
Disclosure versus strategic surprise
Pre-grant opposition exposes prior art early, allowing patentees to amend claims or adjust prosecution strategy.
Revocation proceedings, in contrast, preserve strategic surprise and are often used in later-stage disputes or infringement actions.
-
Forum foreclosure
In Aloys Wobben v. Yogesh Mehra, the Supreme Court held that a party cannot simultaneously pursue revocation by petition and counter-claim. The election of remedy is therefore binding and strategic.[6]
The Patentee’s Defence
-
Section 8 compliance
Continuous and accurate disclosure of foreign filing information is critical. While non-compliance is treated seriously, it does not automatically result in invalidation; courts assess materiality and conduct in context.
-
Specification strength
A strong specification anticipates Section 3 objections and is supported by sufficient technical disclosure. This is particularly significant in pharmaceutical and software-related inventions.
-
Engagement in proceedings
The Opposition Board’s recommendation under Section 25(3) plays a persuasive role in shaping the Controller’s decision. A well-reasoned and evidence-backed response significantly strengthens the patentee’s position.
Industry Patterns
Pharmaceuticals
Highly active opposition landscape. Section 3(d) remains central, and pre-grant opposition is frequently used by generics and public interest groups.
Software and AI
Section 3(k) defines the primary constraint. The focus is on technical effect and claim drafting strategy.
Manufacturing and agrochemicals
Prior art and obviousness dominate. Section 8 compliance continues to be a recurring vulnerability.
After the Order
Post-grant opposition decisions are appealable before the High Courts, following the abolition of the IPAB under the Tribunal Reforms Act, 2021. Appeals are now governed under Section 117A of the Patents Act.
Pre-grant opposition orders do not ordinarily carry a statutory appeal and are typically challenged through writ jurisdiction where maintainable.
Revocation under Section 64 and counter-claims in infringement proceedings remain independent remedies, subject to the doctrine of election of remedies as clarified in Aloys Wobben v. Yogesh Mehra.[7]
Conclusion
Patent opposition in India is not merely a procedural checkpoint, it is a structural feature of the patent ecosystem that shapes how rights are granted, challenged, and ultimately enforced.
For patentees, the system rewards foresight: disciplined disclosure, carefully drafted specifications, and prosecution strategies that anticipate opposition significantly enhance enforceability and valuation. For competitors, the regime provides a meaningful and early-stage opportunity to challenge exclusivity, but success depends on timing, evidentiary discipline, and careful forum selection.
Ultimately, opposition is not an exception to the patent system, it is one of its defining mechanisms.
Understanding its geometry is therefore essential to understanding how patent rights function in practice in India.
[1] Biswanath Prasad Radhey Shyam v. Hindustan Metal Industries Ltd., AIR 1982 SC 1444.
[2] Monsanto Co. v. Coromandel Indag Products (P) Ltd., AIR 1986 SC 712.
[3] Novartis AG v. Union of India, (2013) 6 SCC 1.
[4] UCB Farchim SA v. Cipla Ltd., 2010 (43) PTC 461 (Del).
[5] Dr. Snehlata C. Gupte v. Union of India, 2011 (47) PTC 244 (Del).
[6] Aloys Wobben v. Yogesh Mehra, (2014) 10 SCC 263.
[7] Aloys Wobben v. Yogesh Mehra, (2014) 10 SCC 263.